SEC Form 4 · accession 0001193125-26-299927

LeonaBio, Inc. · LONA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners

Director · 10% Owner

Director · 10% Owner

Director · 10% Owner

Period of report

Jun 23, 2026

Accepted (ET)

Jul 9, 2026 · 6:48 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0001620463

Table I — non-derivative securities

No Table I lines on this filing.

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F2,F1	$8.35	Jun 23, 2026	A	28,000	A	—	Jun 22, 2036	Common Stock	28,000	28,000	I

F1The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy.
F2Joseph Edelman ("Mr. Edelman") is the managing member of Perceptive Advisors LLC (the "Advisor"). The Advisor serves as the investment manager of Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). The Advisor may be deemed to have an indirect pecuniary interest in the securities reported herein because the Advisor has the right to receive the director compensation provided in respect of Mr. Edelman's board service through a partial management fee offset. Each of the Master Fund and the Advisor disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of its indirect pecuniary interest therein, and this report shall not be deemed an admission that either the Master Fund or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.